These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37477875)

  • 1. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial.
    Sáez-Llorens X; Norero X; Mussi-Pinhata MM; Luciani K; de la Cueva IS; Díez-Domingo J; Lopez-Medina E; Epalza C; Brzostek J; Szymański H; Boucher FD; Cetin BS; De Leon T; Dinleyici EC; Gabriel MÁM; Ince T; Macias-Parra M; Langley JM; Martinón-Torres F; Rämet M; Kuchar E; Pinto J; Puthanakit T; Baquero-Artigao F; Gattinara GC; Arribas JMM; Ramos Amador JT; Szenborn L; Tapiero B; Anderson EJ; Campbell JD; Faust SN; Nikic V; Zhou Y; Pu W; Friel D; Dieussaert I; Lopez AG; McPhee R; Stoszek SK; Vanhoutte N
    J Infect Dis; 2024 Jan; 229(1):95-107. PubMed ID: 37477875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
    Díez-Domingo J; Sáez-Llorens X; Rodriguez-Weber MA; Epalza C; Chatterjee A; Chiu CH; Lin CY; Berry AA; Martinón-Torres F; Baquero-Artigao F; Langley JM; Ramos Amador JT; Domachowske JB; Huang LM; Chiu NC; Esposito S; Moris P; Lien-Anh Nguyen T; Nikic V; Woo W; Zhou Y; Dieussaert I; Leach A; Gonzalez Lopez A; Vanhoutte N
    J Infect Dis; 2023 May; 227(11):1293-1302. PubMed ID: 36484484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
    Cicconi P; Jones C; Sarkar E; Silva-Reyes L; Klenerman P; de Lara C; Hutchings C; Moris P; Janssens M; Fissette LA; Picciolato M; Leach A; Gonzalez-Lopez A; Dieussaert I; Snape MD
    Clin Infect Dis; 2020 May; 70(10):2073-2081. PubMed ID: 31340042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated-Dose Toxicity, Biodistribution, and Shedding Assessments With a ChAd155 Respiratory Syncytial Virus Vaccine Candidate Evaluated in Rabbits and Rats.
    Stokes AH; Planty C; Pion J; Ancian P; Rogue A; Bansard C; Silvano J; Papineau D; Ben Abdeljelil N; Maruggi G; Song H; Spickler C; Blouin K; Dubois G; Rodriguez LA; Baumeister J; Steff AM; Destexhe E
    Int J Toxicol; 2022 Aug; 41(4):263-275. PubMed ID: 35653115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
    Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
    J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
    Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
    Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
    J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves.
    de Jong R; Stockhofe-Zurwieden N; Bonsing J; Wang KF; Vandepaer S; Bouzya B; Toussaint JF; Dieussaert I; Song H; Steff AM
    Nat Commun; 2022 Oct; 13(1):6142. PubMed ID: 36253363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
    Beran J; Lickliter JD; Schwarz TF; Johnson C; Chu L; Domachowske JB; Van Damme P; Withanage K; Fissette LA; David MP; Maleux K; Schmidt AC; Picciolato M; Dieussaert I
    J Infect Dis; 2018 Apr; 217(10):1616-1625. PubMed ID: 29401325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
    Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
    J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
    Leroux-Roels I; Davis MG; Steenackers K; Essink B; Vandermeulen C; Fogarty C; Andrews CP; Kerwin E; David MP; Fissette L; Vanden Abeele C; Collete D; de Heusch M; Salaun B; De Schrevel N; Koch J; Verheust C; Dezutter N; Struyf F; Mesaros N; Tica J; Hulstrøm V
    J Infect Dis; 2023 Mar; 227(6):761-772. PubMed ID: 35904987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
    Stuart ASV; Virta M; Williams K; Seppa I; Hartvickson R; Greenland M; Omoruyi E; Bastian AR; Haazen W; Salisch N; Gymnopoulou E; Callendret B; Faust SN; Snape MD; Heijnen E
    J Infect Dis; 2022 Dec; 227(1):71-82. PubMed ID: 36259542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.